中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
4-(1-甲基肼基)-7-硝基苯并呋咱 | 4-(N1-methylhydrazino)-7-nitrobenzofurazan | 214147-22-5 | C7H7N5O3 | 209.164 |
4-氟-7-硝基苯并-2-氧杂-1,3-二唑 | 4-fluoro-7-nitro-2,1,3-benzoxadiazole | 29270-56-2 | C6H2FN3O3 | 183.099 |
4-氯-7-硝基苯并-2-氧杂-1,3-二唑 | NBD chloride | 10199-89-0 | C6H2ClN3O3 | 199.553 |
5-氯-4-硝基-2,1,3-苯噁二唑 | 5-chloro-4-nitrobenzo[c]-[1,2,5]oxadiazole | 5714-17-0 | C6H2ClN3O3 | 199.553 |
—— | 4-methoxy-7-nitro-benzo[1,2,5]oxadiazole | 18333-73-8 | C7H5N3O4 | 195.134 |
Transition‐metal‐catalyzed bioorthogonal reactions emerged a decade ago as a novel strategy to implement spatiotemporal control over enzymatic functions and pharmacological interventions. The use of this methodology in experimental therapy is driven by the ambition of improving the tolerability and PK properties of clinically‐used therapeutic agents. The preclinical potential of bioorthogonal catalysis has been validated